Pembrolizumab FDA Approved for Triple-Negative Breast Cancer

The FDA recently approved pembrolizumab (Keytruda®, Merck & Co) with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) for those whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. In addition, the FDA approved the companion diagnostic, PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.), to select patients with TNBC for pembrolizumab. Efficacy was shown in KEYNOTE-355 (NCT02819518), a multicenter, double-bl...
Continue reading

Paul Sargos, MD on Adjuvant RT versus Salvage RT for Prostate Cancer

Results of a new study presented at American Society of Radiation Oncology (ASTRO) 2020 reveal that adjuvant radiotherapy (aRT) significantly increased the risk of late toxicity compared with salvage radiotherapy (sRT). Lead author of the study, Paul Sargos, MD, discusses the significance of these results in addition to advice for community oncologists treating this patient population in this interview with i3 Health. What was the rationale for this study? Paul Sargos, MD: To understand the impo...
Continue reading

Image Guided Intensity Modulated Radiotherapy Reduces Bowel Toxicity in Cervical Cancer

A recent phase 3 study presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2020 Annual Meeting found that patients with cervical cancer undergoing postoperative adjuvant conventional radiation are more likely to develop late bowel toxicity than those undergoing image guided intensity modulated radiotherapy (IG-IMRT). For this study, results of which are published in the International Journal of Radiation Oncology, Biology, Physics, 300 patients aged 18 to 65 years ol...
Continue reading

Ming Shi, MD, PhD: HAIC/FOLFOX Effective for Hepatocellular Carcinoma

A recent study presented by Ming Shi, MD, PhD and colleagues at ESMO Virtual Congress 2020 found that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) yield more effective results in patients with unresectable hepatocellular carcinoma (HCC) compared with transarterial chemoembolization (TACE). In an interview with i3 Health, Dr. Shi shares insights about the significance of these results, as well as the future of treatment for HCC, and advice ...
Continue reading

FOLFOX Vs TACE: Which Is More Effective for Hepatocellular Carcinoma?

A study presented at ESMO Virtual Congress 2020 revealed that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) yields more effective results in patients with unresectable hepatocellular carcinoma (HCC) compared with transarterial chemoembolization (TACE). For this randomized, multi-center, open-label trial (NCT02973685), results of which are published in Annals of Oncology, 315 patients aged 18 years or older with a primary unresectable HCC tu...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.